Dr. Canfield named urology chief at UTHealth
Urologic oncologist Steven E. Canfield, MD, has been named chief of the division of urology in the department of surgery at The University of Texas Health Science Center at Houston (UTHealth) Medical School.
Urologic oncologist Steven E. Canfield, MD, has been named chief of the division of urology in the department of surgery at The University of Texas Health Science Center at Houston (UTHealth) Medical School.
"Dr. Canfield has served as the program director of the division of urology for the last few years, and it has been a pleasure to work him," said Richard J. Andrassy, MD, professor and chairman of the UTHealth Surgery Department. "We are pleased he has accepted the position of chief of urology."
Dr. Canfield, an associate professor of surgery at UTHealth, specializes in the treatment of prostate, bladder, and kidney cancer. He graduated from Thomas Jefferson University’s Jefferson Medical College in Philadelphia and completed an internship and residency at the Mount Sinai School of Medicine in New York. Later, he finished a 3-year fellowship at the University of Texas MD Anderson Cancer Center, Houston.
Dr. Canfield is the chief of urology at Lyndon B. Johnson General Hospital, Houston, in partnership with the Harris County Hospital District and the MD Anderson Cancer Center. He is an investigator in ongoing clinical trials and has published more than 70 manuscripts, chapters, and editorial reviews.
Dr. Canfield succeeds Dr. Andrassy, who served as interim chief, and O. Lenaine Westney, MD, who left the position in January 2010 and is currently associate professor of urology at the University of Texas MD Anderson Cancer Center, Houston.
Go back to this issue of Urology Times eNews.
Related Content
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.
